ERK1/2 antibody
-
- Target See all ERK1/2 (MAPK1/3) Antibodies
- ERK1/2 (MAPK1/3) (Mitogen-Activated Protein Kinase 1/3 (MAPK1/3))
-
Reactivity
- Human, Mouse
-
Host
- Mouse
-
Clonality
- Monoclonal
-
Conjugate
- This ERK1/2 antibody is un-conjugated
-
Application
- Western Blotting (WB), ELISA, Immunohistochemistry (IHC), Flow Cytometry (FACS)
- Purification
- purified
- Immunogen
- Purified recombinant fragment of human MAPK expressed in E. coli.
- Clone
- 3F8
- Isotype
- IgG2b
- Top Product
- Discover our top product MAPK1/3 Primary Antibody
-
-
- Application Notes
- ELISA: 1:10000, WB: 1:500 - 1:2000, IHC: 1:200 - 1:1000, FCM: 1:200 - 1:400
- Restrictions
- For Research Use only
-
- Format
- Liquid
- Buffer
- Ascitic fluid containing 0.03 % sodium azide.
- Preservative
- Sodium azide
- Precaution of Use
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- Storage
- 4 °C/-20 °C
- Storage Comment
- 4°C, -20°C for long term storage
-
-
Protein kinase Cdelta supports survival of MDA-MB-231 breast cancer cells by suppressing the ERK1/2 pathway." in: The Journal of biological chemistry, Vol. 284, Issue 48, pp. 33456-65, (2009) (PubMed).
: "
-
Protein kinase Cdelta supports survival of MDA-MB-231 breast cancer cells by suppressing the ERK1/2 pathway." in: The Journal of biological chemistry, Vol. 284, Issue 48, pp. 33456-65, (2009) (PubMed).
-
- Target
- ERK1/2 (MAPK1/3) (Mitogen-Activated Protein Kinase 1/3 (MAPK1/3))
- Alternative Name
- p44/42 MAPK (Erk1/2) (MAPK1/3 Products)
- Synonyms
- erk1/2 antibody, mitogen-activated protein kinase antibody, erk1/2 antibody
- Background
-
Description: Mitogen-activated protein kinases (MAPKs) are a widely conserved family of serine/threonine protein kinases involved in many cellular programs such as cell proliferation, differentiation, motility, and death. The p44/42 MAPK (Erk1/2) signaling pathway can be activated in response to a diverse range of extracellular stimuli including mitogens, growth factors, and cytokines and is an important target in the diagnosis and treatment of cancer. Upon stimulation, a sequential three-part protein kinase cascade is initiated, consisting of a MAP kinase kinase kinase (MAPKKK or MAP3K), a MAP kinase kinase (MAPKK or MAP2K), and a MAP kinase (MAPK). Multiple p44/42 MAP3Ks have been identified, including members of the Raf family as well as Mos and Tpl2/Cot. MEK1 and MEK2 are the primary MAPKKs in this pathway. MEK1 and MEK2 activate p44 and p42 through phosphorylation of activation loop residues Thr202/Tyr204 and Thr185/Tyr187, respectively. Several downstream targets of p44/42 have been identified, including p90RSK and the transcription factor Elk-1. p44/42 are negatively regulated by a family of dual-specificity (Thr/Tyr) MAPK phosphatases, known as DUSPs or MKPs, along with MEK inhibitors such as U0126 and PD98059.
Aliases: ERK, p38, p40, p41, ERK2, ERT1, MAPK2, PRKM1, PRKM2, P42MAPK, p41mapk, MAPK1
- Molecular Weight
- 42 kDa
- Gene ID
- 5594
- HGNC
- 5594
-